Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Cardiac Sciences Guidelines
    • AHA/ACC Guidelines to...

    AHA/ACC Guidelines to primary prevention of Sudden Cardiac Death

    Written by Deepanjana Sarkar Published On 2019-06-30T19:00:06+05:30  |  Updated On 30 Jun 2019 7:00 PM IST
    AHA/ACC Guidelines to primary prevention of Sudden Cardiac Death

    Sudden Cardiac Death (SCD) accounts for over half of cardiovascular mortality and is a major public health issue. The American Heart Association (AHA) and the Americal College of Cardiology (ACC) have released a guideline on primary prevention and control of SCDs in early and post Myocardial Infarction (MI).


    The guideline aims at providing a contemporary guideline for the management of adults who have Ventricular Arrhythmia (VA) or who are at risk for SCD, including diseases and syndromes associated with a risk of SCD from VA.


    Sudden cardiac death (SCD) is generally understood by the lay and medical communities as sudden unexpected collapse, without warning. Survival after SCD remains very low and stable, despite major investments by the medical and research communities in this area over the past decades.


    Ventricular Arrhythmia (VA) includes a spectrum of disease that ranges from the premature ventricular complex (PVC) to ventricular fibrillation (VF), with a clinical presentation that ranges from a total lack of symptoms to cardiac arrest. Most life-threatening VAs are associated with ischemic heart disease which is particularly seen in older patients.


    The risks of VA and SCD vary in specific populations with different underlying cardiac conditions, and with specific family history and genetic variants, and this variation has important implications for studying and applying therapies.


    The present guideline is an updated version of the previous guideline. It outlines the key recommendations, changes from previous guidelines, and patient benefits.


    Following are the key recommendation of the guideline provided for primary prevention and control of SCD in patients with ventricular arrhythmia.







    • With reduced EF (<40%), follow guideline-directed medical therapy (GDMT), to include:

      • Beta-blockers;

      • Mineralocorticoid receptor antagonists; and

      • Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor-neprilysin inhibitors.



    • With life expectancy >1 year, where GDMT fails to prevent the following, implanted cardioverter defibrillator (ICD) is recommended:

      • Left ventricular EF (LVEF) ≤35% and ischemic heart disease at 40+ days after myocardial infarction, 90+ days post-revascularization, class II-III heart failure;

      • LVEF ≤30% with ischemic heart disease at 40+ days after myocardial infarction, 90+ days post-revascularization, class I heart failure; or

      • Nonischemic cardiomyopathy, class II-III symptoms, LVEF ≤35%.



    • Biggest guidelines change from earlier versions is the addition of angiotensin receptor-neprilysin inhibitors, which the synopsis authors say remains controversial.

    • Benefits for patients include the focus on GDMT before moving to ICD, with the parameter of expected survival >1 year.


    For more reference please click on the link


    https://doi.org/10.1161/CIR.0000000000000549





    beta blockerscardiac arrestcardiovascular mortalityGDMTHeart diseaseICDischemic heart diseaseLVEFMImineralocorticoidmyocardial infarctionpremature ventricular complexPVCSCASCDsudden cardiac arrestsudden cardiac deathVAventricular arrhythmiaventricular fibrillationVFβ Blockers

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Deepanjana Sarkar
    Deepanjana Sarkar
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok